In a phase II clinical trial, treating gastric cancer patients with Olaparib and paclitaxel led to a greater increase in overall survival among the subgroup of patients with low ATM expression (HR 0.35, 80%CI 0.22 to 0.56, P < 0.002) than among the overall population (HR 0.56, 80%CI 0.41 to 0.75, P = 0.005) [33]. Here, ATM is linked to gastric cancer.